Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2009 Mar 26;113(13):2895-901.
doi: 10.1182/blood-2008-07-170449. Epub 2008 Nov 6.

New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment

Affiliations
Multicenter Study

New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment

Francisco Cervantes et al. Blood. .

Abstract

Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation and new investigational drugs. To enhance this process by developing a highly discriminative prognostic system, 1054 patients consecutively diagnosed with PMF at 7 centers were studied. Overall median survival was 69 months (95% confidence interval [CI]: 61-76). Multivariate analysis of parameters obtained at disease diagnosis identified age greater than 65 years, presence of constitutional symptoms, hemoglobin level less than 10 g/dL, leukocyte count greater than 25 x 10(9)/L, and circulating blast cells 1% or greater as predictors of shortened survival. Based on the presence of 0 (low risk), 1 (intermediate risk-1), 2 (intermediate risk-2) or greater than or equal to 3 (high risk) of these variables, 4 risk groups with no overlapping in their survival curves were delineated; respective median survivals were 135, 95, 48, and 27 months (P< .001). Compared with prior prognostic models, the new risk stratification system displayed higher predictive accuracy, replicability, and discriminating power. In 409 patients with assessable metaphases, cytogenetic abnormalities were associated with shorter survival, but their independent contribution to prognosis was restricted to patients in the intermediate-risk groups. JAK2V617F did not cluster with a specific risk group or affect survival.

Comment in

Similar articles

See all similar articles

Cited by 299 articles

  • Systemic Mastocytosis with Associated Primary Myelofibrosis.
    Greco M, Caocci G, Mascia R, Nemolato S, Deidda M, Simula MP, Barca MP, Orrù S, La Nasa G. Greco M, et al. Indian J Hematol Blood Transfus. 2020 Apr;36(2):442-443. doi: 10.1007/s12288-019-01225-3. Epub 2019 Oct 28. Indian J Hematol Blood Transfus. 2020. PMID: 32425413 No abstract available.
  • Survival following allogeneic transplant in patients with myelofibrosis.
    Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Gowin K, et al. Blood Adv. 2020 May 12;4(9):1965-1973. doi: 10.1182/bloodadvances.2019001084. Blood Adv. 2020. PMID: 32384540 Free PMC article.
  • Multi-focal Lytic Lesions in a Patient with Myelofibrosis: A Case Report.
    Burnham RR Jr, Johnson B, Lomasney LM, Borys D, Cooper AR. Burnham RR Jr, et al. Cureus. 2020 Mar 30;12(3):e7475. doi: 10.7759/cureus.7475. Cureus. 2020. PMID: 32351853 Free PMC article.
  • Management of myelofibrosis after ruxolitinib failure.
    Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
  • Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.
    Zhang L, Yang F, Feng S. Zhang L, et al. Ther Adv Hematol. 2020 Feb 13;11:2040620720906002. doi: 10.1177/2040620720906002. eCollection 2020. Ther Adv Hematol. 2020. PMID: 32110286 Free PMC article. Review.
See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback